In a regional first, Xiaogan Central Hospital successfully performed a laparoscopic distal gastrectomy for gastric cancer using the SHURUI® single-port robotic system. Led by Dr. Huang Weijiang, the surgical team treated a 60-year-old patient with a 4.5 cm gastric lesion located in the lower third of the stomach. The case was complicated by a prior abdominal surgery and severe adhesions.
Through a single 3.5 cm umbilical incision, the SHURUI® system’s snake-like instruments enabled precise lymph node dissection and reconstruction with minimal blood loss. The operation was completed in just under 2 hours, and the patient recovered smoothly, ambulating within a day.
This marks a milestone in minimally invasive oncology surgery in central China and highlights SHURUI®’s ability to deliver precision, reduced trauma, and faster recovery, even in complex scenarios. It demonstrates how Chinese robotic innovation is advancing the frontiers of ultra-minimally invasive cancer treatment.
Important Notes
The Single-port Endoscopic Surgical System (SR-ENS-600), developed and produced by Beijing Surgerii Robotics Company Limited, has been approved by the National Medical Products Administration (NMPA) in China for urology and gynecology laparoscopic surgeries. Surgeons who wish to learn the surgical operations of the SHURUI robot should contact Beijing Surgerii Robotics Co., Ltd. to participate in the official training program. Patients who want to participate in the registered clinical trials of the SHURUI robot should contact the official cooperative hospitals of Surgerii and consult with surgeons to determine their suitability for surgery with the SHURUI robot. Both surgeons and patients should carefully understand all information regarding the performance of surgeries by the SHURUI robot and its potential risks.
Beijing Surgerii Robotics Co., Ltd. owns Surgerii®, SHURUI®, and other
trademarks and may not be used without permission.
